Tetraphase Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TETRAPHASE PHARMS, and what generic alternatives to TETRAPHASE PHARMS drugs are available?
TETRAPHASE PHARMS has one approved drug.
There are four US patents protecting TETRAPHASE PHARMS drugs.
There are seventy-one patent family members on TETRAPHASE PHARMS drugs in thirty-three countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Tetraphase Pharms
International Patents: | 71 |
US Patents: | 4 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Tetraphase Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 10,961,190 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 11,578,044 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | 8,906,887 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tetraphase Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3529236 | ⤷ Try a Trial |
Japan | 2019531321 | ⤷ Try a Trial |
Spain | 2558512 | ⤷ Try a Trial |
Serbia | 53003 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tetraphase Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2323972 | PA2019009 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
2323972 | 2019C/511 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
2323972 | 2019010 | Norway | ⤷ Try a Trial | PRODUCT NAME: ERAVASYKLIN ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1312 20181025 |
2323972 | 122019000024 | Germany | ⤷ Try a Trial | PRODUCT NAME: ERAVACYCLIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.